Investment & Collaboration Opportunities
APIE Therapeutics is developing strong, exclusive global IP through Apelinergic system targets
We have a strong and long-term commitment to develop first-in-class therapies for chronic diseases
APIE Therapeutics will initiate a $20M Series A raise in Q1 of 2021 to carry the lead compound APT101 from IND enabling through clinical Phase IIa trials, including endpoints for two orphan indications: idiopathic pulmonary fibrosis and kidney nephrotic syndrome. Phase 1 clinical trials are anticipated to begin in Q2 of 2022.
We are looking for collaborations to develop drug programs in the following diseases: